MENU
LMAT
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

LMAT stock forecast, quote, news & analysis

LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease... Show more

LMAT
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for LMAT with price predictions
Oct 01, 2026

Momentum Indicator for LMAT turns positive, indicating new upward trend

LMAT saw its Momentum Indicator move above the 0 level on September 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 104 similar instances where the indicator turned positive. In 75 of the 104 cases, the stock moved higher in the following days. The odds of a move higher are at 72%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for LMAT just turned positive on August 28, 2026. Looking at past instances where LMAT's MACD turned positive, the stock continued to rise in 34 of 50 cases over the following month. The odds of a continued upward trend are 68%.

Following a +1.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where LMAT advanced for three days, in 232 of 341 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LMAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.

LMAT broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for LMAT entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.480) is normal, around the industry mean (5.011). P/E Ratio (28.790) is within average values for comparable stocks, (163.451). Projected Growth (PEG Ratio) (2.178) is also within normal values, averaging (4.456). Dividend Yield (0.012) settles around the average of (0.005) among similar stocks. P/S Ratio (7.267) is also within normal values, averaging (56.074).

The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. LMAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Dividends

LMAT paid dividends on September 03, 2026

LeMaitre Vascular LMAT Stock Dividends
А dividend of $0.25 per share was paid with a record date of September 03, 2026, and an ex-dividend date of August 20, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 8.89B. The market cap for tickers in the group ranges from 126 to 146.54B. ISRG holds the highest valuation in this group at 146.54B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -2%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 14%. CUPR experienced the highest price growth at 34%, while NXGL experienced the biggest fall at -32%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 2%. For the same stocks of the Industry, the average monthly volume growth was 30% and the average quarterly volume growth was 19%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 58
Price Growth Rating: 54
SMR Rating: 81
Profit Risk Rating: 96
Seasonality Score: 15 (-100 ... +100)
View a ticker or compare two or three
LMAT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a manufacturer of vascular devices for vascular surgeons

Industry PharmaceuticalsOther

Industry
Medical Specialties
Address
63 Second Avenue
Phone
+1 781 221-2266
Employees
655
Web
https://www.lemaitre.com